Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

STUDIES OF THE DEPENDENCE-PRODUCING POTENTIAL OF THE NARCOTIC ANTAGONIST 2-CYCLOPROPYLMETHYL-2'-HYDROXY-5,9-DIMETHYL-6,7-BENZOMORPHAN (CYCLAZOCINE, WIN-20,740, ARC II-C-3)

W. R. Martin, H. F. Fraser, C. W. Gorodetzky and D. E. Rosenberg
Journal of Pharmacology and Experimental Therapeutics December 1965, 150 (3) 426-436;
W. R. Martin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. F. Fraser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. W. Gorodetzky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. E. Rosenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effects of single doses and chronic administration of cyclazocine have been studied in nontolerant postaddicts, as well as in postaddicts physically dependent upon morphine. In addition, cyclazocine has been compared with morphine sulfate and nalorphine hydrochloride.

Single dose studies indicate that cyclazocine produces a degree of euphoria, and that maximal euphoric effects are produced with doses of the order of magnitude of 1 mg/70 kg. The subjective effects produced by cyclazocine, however, are qualitatively different from those produced by morphine and most closely resemble those of nalorphine. In addition, larger doses of cyclazocine (1.0 and 2.0 mg/70 kg) produced certain effects which resembled, at least superficially, those produced by barbiturates.

Cyclazocine does not suppress abstinence in subjects physically dependent on morphine; on the contrary, it precipitates abstinence in a manner similar to that of nalorphine.

Subjects chronically intoxicated with 13.2 mg/70 kg/day of cyclazocine, using a gradually progressing dose schedule, showed definite evidence of tolerance to cyclazocine, cross tolerance to nalorphine, and exhibited a definite abstinence syndrome when cyclazocine was withdrawn. The predominant signs of abstinence from cyclazocine consisted of an increase in body temperature, mydriasis, loss of appetite, decrease in body weight, and tachycardia. The abstinence syndrome was slow in developing, first becoming apparent on the third or fourth day following withdrawal, and reaching a maximum on the seventh day of abstinence. Minimal signs of abstinence were seen as long as 6 weeks following withdrawal. The abstinence syndrome was qualitatively different from that from morphine. Although cyclazocine produces a type of euphoria, tolerance, and physical dependence, the bulk of evidence indicates that this agent is qualitatively different from morphine. In general, the effects of cyclazocine most closely resembled those of nalorphine.

In conclusion, cyclazocine should not be classified as a morphine-like analgesic and its potential for abuse by narcotic addicts is regarded as being very low. Whether it would be abused on the basis of other pharmacologic properties, particularly for its sedative characteristics, cannot be predicted on the basis of these experiments.

Footnotes

    • Accepted July 1, 1965.
  • The Williams & Wilkins Comapny

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 150, Issue 3
1 Dec 1965
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
STUDIES OF THE DEPENDENCE-PRODUCING POTENTIAL OF THE NARCOTIC ANTAGONIST 2-CYCLOPROPYLMETHYL-2'-HYDROXY-5,9-DIMETHYL-6,7-BENZOMORPHAN (CYCLAZOCINE, WIN-20,740, ARC II-C-3)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

STUDIES OF THE DEPENDENCE-PRODUCING POTENTIAL OF THE NARCOTIC ANTAGONIST 2-CYCLOPROPYLMETHYL-2'-HYDROXY-5,9-DIMETHYL-6,7-BENZOMORPHAN (CYCLAZOCINE, WIN-20,740, ARC II-C-3)

W. R. Martin, H. F. Fraser, C. W. Gorodetzky and D. E. Rosenberg
Journal of Pharmacology and Experimental Therapeutics December 1, 1965, 150 (3) 426-436;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

STUDIES OF THE DEPENDENCE-PRODUCING POTENTIAL OF THE NARCOTIC ANTAGONIST 2-CYCLOPROPYLMETHYL-2'-HYDROXY-5,9-DIMETHYL-6,7-BENZOMORPHAN (CYCLAZOCINE, WIN-20,740, ARC II-C-3)

W. R. Martin, H. F. Fraser, C. W. Gorodetzky and D. E. Rosenberg
Journal of Pharmacology and Experimental Therapeutics December 1, 1965, 150 (3) 426-436;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Discriminative Stimulus Effects of Zolpidem in Squirrel Monkeys: Comparison with Conventional Benzodiazepines and Sedative-Hypnotics
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics